

## Speakers



Dr Carmen Boix Bernardini  
Almirall



Dr Steffen Groß  
PEI



Dr Hiltrud Horn  
Horn Pharmaceutical Consulting



Dr Line Lundsberg-Nielsen  
Lundsberg Consulting

# ICH Q8 / ICH Q11 Training Course

From QbD to Process Validation



Live Online Training on 23/24 November 2021



**Small & Biotech Molecules will be covered:  
Development, Process Validation, Lifecycle Approach (ICH Q12),  
Control Strategy / PAT / RTRT**

## Highlights

- Quality by Design (QbD)
- Quality Target Product Profile (QTPP)
- Critical Quality Attributes (CQA)
- Critical Process Parameters (CPP)
- DoE Examples
- Design Space (DS)
- Control Strategy
- Process Analytical Technology (PAT)/RTRT
- ICH Q8 and ICH Q11
- ICH Q12: A Lifecycle Approach to Process Validation



Save money and book this live online training course in combination with the „ICH Q12 Training Course - How to use the PACMP in Practice“ on 25 November 2021!

## Objectives

You will be updated on the latest regulatory developments and learn how to apply the respective paradigms in Pharmaceutical Development to be better able to design strategies for the implementation of Quality by Design (QbD) according to ICH Q8 and ICH Q11.

During this Live Online Training elements and methodologies associated with ICH Q8 and ICH Q11 will be discussed. All this will be illustrated with examples and case studies.

## Background

The impact of ICH Q8, Q9, Q10, and Q11 is changing both the regulatory expectations and the strategies of Pharmaceutical Development, and this impact will continue to grow, especially in view of the emerging ICH Q12 Guideline.

The QbD concept described in ICH Q8 and ICH Q11 have to be seen as an overarching paradigm and an interdisciplinary approach across the product lifecycle. It also systematically emphasises enhanced product and process understanding throughout the product lifecycle.


Ideally, application of ICH Q8 and ICH Q11 elements already starts in the early design phase of a drug product where both patient needs and process design are considered. The QbD concept requires a comprehensive understanding of the chemical and physical nature of the individual active substance(s) and excipients, and of the way their attributes interact in the formulation and how they are impacted by the manufacturing process. During the design phase, it is important to establish the Quality Target Product Profile (QTPP), determine the Critical Quality Attributes (CQAs), identify Critical Process Parameters (CPPs) and Material Attributes (material CQAs) and to understand how the process parameters and material attributes affect the CQAs. The relationship between process inputs (material attributes and process parameters) and the CQAs is described in the Design Space and ensured during manufacturing with an enhanced control strategy, leading to improved process understanding, greater operational flexibility and opportunities for more efficient life cycle management activities.

ICH Q8 combined with the new Q12 will open the door to a powerful era of refined, modern and efficient pharmaceutical development and optimization for those companies who are ready to invest in this new paradigm.

## Target Audience

This Live Online Training is designed for all scientists, engineers, managers and executives from Pharmaceutical and Biotech Development units and support functions to Manufacturing, including Quality Assurance and Technical/CMC Regulatory Affairs, who are involved in the implementation of ICH Q8/Q11 elements.


## Programme Day 1

 Provisional timetable, the actual schedule may vary depending on the situation

09.00 - 09.15 h Welcome and Introduction

09.15 - 10.15 h QbD for Drug Products: Background and Practical Aspects

- Essentials to know about QbD
- Steps for defining QTPP/CQA/ CPP
- Benefits of the QbD Approach
- Practical Examples


 10.15 - 11.00 h  
QbD for Drug Products

- QTPP – CQA – CPP for different kinds of formulations, e.g. Oral formulations (Tablets, vs. Biotech vs. Vaccines)

11.00 - 11.15 h Break

11.15 - 12.15 h QbD - Regulatory Perspective

- Current state of PAT & QbD implementation and regulatory challenges
- Quality by on-line (PAT) measurements
- Real time release testing: general considerations
- Going forward: ICH Q12 / Q13 / Q14

 12.15 - 12.45 h Q&A Session 1

12.45 - 13.45 h Break


13.45 - 15.15 h DoE Examples for API Development

- DoE theory:
  - Resolution and confounding
  - Overview of available DoE designs
  - Basic statistics – understanding my software analysis
  - Intuitive interpretation of the design: mapping
- Practical approach to DoE aimed to reduce the number of experiments:
  - Risk assessment: Fishbone (Ishikawa) diagram; FMEA (failure Mode Effect Analysis) and RPN analysis (Risk Priority Number)
  - Choosing the design
  - Practical tips for execution

15.15 - 15.30 h Break

15.30 - 16.30 h Development of the Drug Substance/ Drug Product (incl. Biotech)

- Strategies to consider for development
- Key points and potential pitfalls
- Ways to success for the submission of the dossier
- Typical questions from regulators

 16.30 - 17.00 h Q&A Session 2

## Programme Day 2

### 09.00 - 10.00 h QbD for Drug Products

- Typical Points of Discussions within Teams
- Keypoints and potential pitfalls
- Ways to success for the submission of the dossier
- Typical questions from regulators

### 10.00 - 11.00 h How the QbD derived Control Strategy defines Process Validation

- QbD and PAT as an enabler for gaining Process Understanding and designing the process and the control strategy, PV stage 1 (establishing the control strategy)
- Different approaches to PV/PPQ depending on the type of control strategy, PV stage 2 (traditional, continuous process verification or hybrid approach used to verify the control strategy)
- Ongoing/Continued Process verification, PV stage 3 (verifying the validity and robustness of the control strategy)

### 11.00 - 11.15 h Break

### 11.15 - 12.15 h Process Validation - Case Study (Small Molecule Drug Product)

Case study related to the previous presentation (PV stage 1 and 2)

- Case example of a solid dosage form process enabled by a QbD approach
- Establishing the control strategy: Examples of the application of PAT/RTTR
- Validation of the process – verification of the control strategy

### 12.15 - 13.00 h Ongoing Process Verification and Lifecycle Approach of a Process established from QbD Principles

- Continuous process verification versus continued/ongoing process verification (PV stage 3)
- Case study – the continuation of the example from above (PV stage 3)
- ICH Q12, performance-based control and the link to PAT
- Life cycle management of the product, process and control strategy opportunities for a product developed using of a QbD principles



### 12.30 - 13.30 h Q&A Session 3

#### Participant's comment from the May 2018 course:

*"Excellent speakers!"*

Gordana Savi, Croatian Agency for Medicinal Products and Medical Devices

## Speakers



**Dr Carmen Boix Bernardini, Almirall, Spain**  
Carmen received her PhD in Organic Chemistry from the University of Valencia (Spain). After two years as Marie Curie post-doctoral Fellow (University of Nottingham), she joined the GSK Operations (UK) in 1999 as process chemist for new APIs, where she had her first contact with QbD. She has over 20 years of experience in development and optimization of chemical processes by QbD methodology. Currently, she is responsible for the industrialization of APIs in Ranke Química (Almirall chemical plant) in Barcelona.



**Dr Steffen Groß, Paul-Ehrlich-Institut (PEI) Federal Institute for Vaccines and Biomedicines, Germany**

Steffen Groß received his PhD degree from the Max Planck Research Unit Molecular Cell Biology Jena, Germany. Today, he is Head Section Monoclonal and Polyclonal Antibodies and Scientific Assessor (Quality, Pre-clinic) at the Paul-Ehrlich Institute (PEI).



**Dr Hiltrud Horn, Horn Pharmaceutical Consulting, Germany**

Hiltrud is managing director of HORN Pharmaceutical Consulting with focus on CMC, GMP and Regulatory Affairs (EU and US). She started in pharma industry in 1990 and held several managerial positions within Hoffmann-La Roche and Knoll (now Abbott) with global responsibility within QC / QA / Regulatory Affairs / Project Management / Medical Writing. She was consultant for the biotech and life science industry at Cap Gemini Ernst & Young prior to starting her own business.



**Dr Line Lundsberg-Nielsen Lundsberg Consulting Ltd., UK**

Line is a scientist and runs her own consultancy business focusing on applying a science and risk based approach for pharmaceutical development, process design, technology transfer, qualification and process validation. She has many years of experience within the pharmaceutical industry and has a theoretical as well as practical approach to QbD, PAT and RTTR from working at Novo Nordisk and Lundbeck before being a consultant. Line is an active ISPE member and has had different chairing roles and is a well-recognized international speaker and instructor

### GMP/GDP Certification Scheme

Building on your education the ECA GMP/GDP certification programmes provide you with the appropriate supplement to acquire this qualification. This training course is the first element for your additional certification. Simply choose any three courses within the programme according to your professional interest. Your certificate is then valid for two years. To renew it, you can pick any training from the ECA courses and conferences list within that two-years period allowing you to broaden your knowledge in GMP and GDP compliance. Please find more information at [www.gmp-certification.org](http://www.gmp-certification.org)

If the bill-to-address deviates from the specifications on the right, please fill out here:

Reservation Form (Please complete in full)



## Live Online Training Courses

- ICH Q8 / ICH Q11 Training Course - From QbD to Process Validation, 23/24 November 2021
- ICH Q12 - How to use the PACMP in Practice, 25 November 2021

\_\_\_\_\_  
Title, first name, surname

\_\_\_\_\_  
Department

\_\_\_\_\_  
Company

\_\_\_\_\_  
Important: Please indicate your company's VAT ID Number

\_\_\_\_\_  
Purchase Order Number, if applicable

\_\_\_\_\_  
City

\_\_\_\_\_  
Country

\_\_\_\_\_  
Phone / Fax

\_\_\_\_\_  
E-Mail (Please fill in)

CONCEPT HEIDELBERG  
P.O. Box 101764  
Fax +49(0) 62 21/84 44 34

D-69007 Heidelberg  
GERMANY

### General terms and conditions

If you cannot attend the conference you have two options:

1. We are happy to welcome a substitute colleague at any time.

2. If you have to cancel entirely we must charge the following processing fees:

- Cancellation until 2 weeks prior to the conference 10 %

- Cancellation until 1 week prior to the conference 50 %

- Cancellation within 1 week prior to the conference 100 %.

CONCEPT HEIDELBERG reserves the right to change the materials, instructors,

or speakers without notice or to cancel an event.

If the event must be cancelled, registrants will be notified as soon as possible

and will receive a full refund of fees paid. CONCEPT HEIDELBERG will not be

responsible for discount airfare penalties or other costs incurred due to a

cancellation.

Terms of payment: Payable without deductions within 10 days after receipt of

invoice.

Important: This is a binding registration and above fees are due in case of

cancellation or non-appearance. If you cannot take part, you have to inform us

in writing. The cancellation fee will then be calculated according to the point of

time at which we receive your message.

In case you do not appear at the event without having informed us, you will have

to pay the full registration fee, even if you have not made the payment yet. Only

after we have received your payment, you are entitled to participate in the

conference (receipt of payment will not be confirmed)! (As of January 2012).

German law shall apply. Court of jurisdiction is Heidelberg.

Privacy Policy: By registering for this event, I accept the processing of my Personal Data. Concept Heidelberg will use my data for the processing of this order, for which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at [http://www.gmp-compliance.org/eca\\_privacy.html](http://www.gmp-compliance.org/eca_privacy.html)). I note that I can ask for the modification, correction or deletion of my data at any time via the contact form on this website.



## Date of the Live Online Training

Tuesday, 23 November 2021, 9.00 to 17.00 h CET

Wednesday, 24 November 2021, 9.00 to 13.30 h CET

## Technical Requirements

For our Live Online Training Courses and Webinars, we use Cisco WebEx, one of the leading suppliers of online meetings. At <https://www.webex.com/test-meeting.html> you can check if your system meets the necessary requirements for the participation at a WebEx meeting and at the same time install the necessary plug-in. Please just enter your name and email address for the test. If the installation is not possible because of your rights for the computer system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and easy.

## Fees (per delegate, plus VAT)

ECA Members € 1,590

APIC Members € 1,690

Non-ECA Members € 1,790

EU GMP Inspectorates € 895

The conference fee is payable in advance after receipt of invoice.



## Would you like to save money?

If you book the live online trainings "ICH Q8/ Q11 Training Course" and "ICH Q12 Training Course - How to use the PACMP in Practice" (25 November 2021) simultaneously the fee reduces as follows:

ECA Members € 2,290

APIC Members € 2,390

Non-ECA Members € 2,490

EU GMP Inspectorates € 1,440

## Registration

Via the attached reservation form, by e-mail or by fax message. Or you register online at [www.gmp-compliance.org](http://www.gmp-compliance.org)

## Presentations/Certificate

The presentations will be made available to you prior to the Live Online Training as PDF files. After the event, you will automatically receive your certificate of participation.

## Conference language

The official conference language will be English.

## Organisation and Contact

ECA has entrusted Concept Heidelberg with the organisation of this event.

CONCEPT HEIDELBERG

P.O.Box 10 17 64

69007 Heidelberg, Germany

Phone +49(0)62 21/84 44-0

Fax +49(0)62 21/84 44 34

[info@concept-heidelberg.de](mailto:info@concept-heidelberg.de)

[www.concept-heidelberg.de](http://www.concept-heidelberg.de)

For questions regarding content please contact:

Dr Andrea Kühn-Hebecker (Director Operations) at

+49(0)62 21/84 44 35 or per e-mail at

[kuehn@concept-heidelberg.de](mailto:kuehn@concept-heidelberg.de)

For questions regarding organisation please contact:

Mr Rouwen Schopka (Organisation Manager) at

+49(0)62 21/84 44 13, or per e-mail at

[schopka@concept-heidelberg.de](mailto:schopka@concept-heidelberg.de)